Drug Identification System

PillID

Home Drugs Search Interactions Compare Blog 🌙

Opioid vs. Non-Opioid Pain Management: A Complete Guide

Pain is the most common reason Americans seek medical care, and choosing how to treat it is one of the most consequential decisions in clinical medicine. Get it wrong in one direction and you leave a patient suffering needlessly; get it wrong in the other direction and you contribute to a crisis that has claimed more than 500,000 American lives over the past two decades. The tension between those two imperatives — relieving suffering and avoiding harm — defines modern pain management.

For much of the late 1990s and 2000s, the pendulum swung hard toward opioids. Pharmaceutical companies aggressively marketed opioid painkillers as safe and non-addictive for chronic pain. Pain was declared "the fifth vital sign." Prescribing rates climbed to levels that, in retrospect, were clearly unsustainable. The consequences are now well-documented: an epidemic of opioid use disorder and overdose death that continues to evolve as prescription opioids gave way to illicit fentanyl as the dominant driver of overdose fatalities.

The pendulum has since corrected — but not without complications. Some patients with legitimate chronic pain found themselves abruptly tapered or denied opioid therapy that had been working for them, creating a different set of harms. The 2022 CDC Clinical Practice Guideline for Prescribing Opioids tried to restore nuance: non-opioid first for most conditions, but flexible and individualized rather than dogmatic, and explicit in affirming that patients with cancer, sickle cell disease, and serious illness deserve different consideration.

This guide explains the full landscape — how pain works, what non-opioid options are available and for what types of pain, when opioids are genuinely appropriate, what the risks are, how opioid use disorder is treated, and how to think about the multi-drug approaches that tend to work best. It is intended as a reference, not a prescription: decisions about individual pain management should always be made in partnership with a healthcare provider who knows your full clinical picture.

Understanding Pain: Not All Pain Is the Same

Pain is not a single phenomenon with a single treatment. Matching treatment to pain type is one of the core principles of modern pain medicine, and understanding a few key distinctions goes a long way toward explaining why some medications work brilliantly for one kind of pain and barely at all for another.

Acute vs. Chronic Pain

Acute pain is pain with a clear, recent cause — a broken bone, a surgical incision, a kidney stone, a severe muscle pull. It is the body's alarm system working correctly: warning you of tissue damage or a threat. Acute pain typically resolves as the underlying injury heals. It often responds well to short-term pharmacological treatment, including both non-opioids and, when severity warrants, opioids for limited durations.

Chronic pain is pain that persists beyond the expected time for tissue healing — typically defined as three to six months or more. Chronic pain is not simply prolonged acute pain; it involves fundamental changes in how the nervous system processes pain signals. The alarm that was once appropriate becomes a default state. This distinction matters enormously for treatment: the drugs and strategies that work for acute pain are often poorly suited to chronic pain, and relying on them long-term can create more problems than they solve.

Nociceptive, Neuropathic, and Central Sensitization Pain

Nociceptive pain arises from actual or threatened tissue damage — the classic kind of pain from injury or inflammation. Inflammatory nociceptive pain (arthritis, post-surgical swelling, tendinitis) responds particularly well to anti-inflammatory drugs. Mechanical nociceptive pain from muscle strain or structural problems may respond to muscle relaxants and physical therapy. Most of the body's pain-signaling system was designed to handle this category.

Neuropathic pain arises from damage or dysfunction within the nervous system itself — not from tissue damage, but from injured or malfunctioning nerves. Diabetic peripheral neuropathy, postherpetic neuralgia (nerve pain following shingles), trigeminal neuralgia, and chemotherapy-induced neuropathy are classic examples. Neuropathic pain characteristically has shooting, burning, electric-shock-like qualities, or numbness and tingling. Critically, neuropathic pain responds poorly to NSAIDs and often poorly to opioids, but responds well to medications targeting neuronal excitability — gabapentin, pregabalin, duloxetine, and certain antidepressants.

Central sensitization is a state in which the central nervous system — the brain and spinal cord — becomes hypersensitized, amplifying pain signals beyond what peripheral tissue damage would explain. Fibromyalgia, some presentations of chronic low back pain, irritable bowel syndrome, and chronic headache disorders involve elements of central sensitization. These conditions respond best to treatments that modulate central pain processing: certain antidepressants and anticonvulsants, cognitive behavioral therapy, graded exercise, and sleep improvement — often not to opioids or conventional anti-inflammatory drugs.

The WHO Pain Ladder and the 2022 CDC Guidelines

The World Health Organization's analgesic ladder, originally developed in the 1980s for cancer pain, established the principle of stepwise escalation: start with non-opioid analgesics, move to weak opioids if those are insufficient, then strong opioids for severe refractory pain. While the ladder was designed for cancer pain and has since been refined, its fundamental logic — begin with the least potentially harmful effective therapy — remains central to pain management philosophy.

The 2022 CDC Clinical Practice Guideline for Prescribing Opioids (which updated the more rigid 2016 version) codified this approach for non-cancer chronic pain with important nuance. Key recommendations include: non-opioid therapies are preferred for subacute and chronic pain; when opioids are used, they should be combined with non-opioid therapy; the lowest effective amount for the shortest clinically appropriate duration should be used; risks and benefits should be discussed using shared decision-making; and treatment should be regularly reassessed. Importantly, the 2022 guidelines explicitly stated they are not intended to be applied as hard limits that override clinical judgment or deny care to patients with complex needs.

Non-Opioid Pain Management: The First Line

The breadth of effective non-opioid options is often underappreciated. For many pain conditions — including moderate acute pain and most chronic pain — non-opioid therapies deliver comparable or superior outcomes to opioids, with significantly better long-term safety profiles. The key is knowing which tool fits which pain type.

NSAIDs: Nonsteroidal Anti-Inflammatory Drugs

NSAIDs are among the most widely used medications in the world, and for inflammatory pain — arthritis, tendinitis, bursitis, menstrual cramps, dental pain, post-injury swelling — they are genuinely excellent. The mechanism: NSAIDs inhibit cyclooxygenase enzymes (COX-1 and COX-2), which are essential for the production of prostaglandins. Prostaglandins are local signaling molecules that sensitize pain receptors, promote inflammation, and raise body temperature. Block prostaglandin synthesis and you reduce pain, inflammation, and fever simultaneously.

Ibuprofen (Advil, Motrin) is a non-selective COX inhibitor — it blocks both COX-1 and COX-2. COX-1 is constitutively expressed in the stomach lining, where it helps maintain the protective mucus barrier and regulates platelet aggregation. Inhibiting COX-1 is the source of the most clinically significant NSAID side effects: gastrointestinal irritation, ulcers, and increased bleeding risk. Ibuprofen is available over the counter and by prescription, and is effective for a wide range of inflammatory and musculoskeletal pain conditions.

Naproxen (Aleve, Naprosyn) is also non-selective but has a longer duration of action than ibuprofen, allowing twice-daily or even once-daily dosing. Some cardiovascular data suggest naproxen may have a marginally more favorable cardiovascular profile compared to other NSAIDs, though the evidence is not entirely consistent. Like ibuprofen, it carries GI and cardiovascular risks.

Celecoxib (Celebrex) is a selective COX-2 inhibitor. By sparing COX-1, it causes significantly less GI irritation and ulceration than non-selective NSAIDs — a clinically meaningful advantage for patients who require long-term NSAID therapy, particularly older adults or those with a history of GI bleeding. However, COX-2 inhibition has cardiovascular implications: prostaglandins regulated by COX-2 help maintain vascular tone and platelet balance, and selective COX-2 inhibitors have been associated with increased cardiovascular risk. The rofecoxib (Vioxx) withdrawal in 2004 highlighted this concern. Celecoxib remains on the market and in use, but with appropriate attention to cardiovascular risk factors.

All NSAIDs carry kidney risk with prolonged use or in dehydrated states, and should be avoided or used very cautiously in patients with chronic kidney disease, heart failure, or significant cardiovascular disease. They should generally be avoided in late pregnancy due to effects on fetal renal function and ductus arteriosus.

Acetaminophen

Acetaminophen (Tylenol, paracetamol) is the most widely used analgesic in the United States and occupies a distinct mechanistic niche: it relieves pain and fever, but is not anti-inflammatory. Its precise mechanism remains somewhat debated — it is thought to act centrally, modulating pain processing in the brain and spinal cord rather than blocking peripheral prostaglandin synthesis in the way NSAIDs do. This makes it useful for pain that lacks a strong inflammatory component — tension headaches, mild osteoarthritis, general aches and fever — while making it ineffective for inflammatory conditions like rheumatoid arthritis flares or acute tendinitis, where the inflammatory component is central to the pain.

Acetaminophen's major safety concern is hepatotoxicity — liver damage — at elevated cumulative amounts. The liver metabolizes acetaminophen through several pathways, one of which produces a toxic intermediate (NAPQI) that is normally neutralized by glutathione. When acetaminophen load exceeds the liver's detoxification capacity — whether through a single large amount (intentional overdose) or through chronic high-level use — NAPQI accumulates and causes hepatocellular damage. Acetaminophen overdose is the leading cause of acute liver failure in the United States. Alcohol use significantly increases risk, because it both induces the pathway that generates NAPQI and depletes glutathione. Patients with pre-existing liver disease require careful monitoring with any acetaminophen use.

Within recommended limits, acetaminophen is notably safer than NSAIDs for patients with cardiovascular disease, kidney disease, or GI vulnerability. It is generally considered the preferred oral analgesic for elderly patients with chronic pain, provided liver function is adequate and alcohol consumption is minimal.

Topical Analgesics

Topical analgesics deliver medication directly to the site of pain with minimal systemic absorption, offering effective relief with a dramatically reduced risk of whole-body side effects. They are particularly valuable for localized musculoskeletal and neuropathic pain.

Topical diclofenac (Voltaren gel, Pennsaid solution) is an NSAID formulated for skin application. Applied directly over a painful joint or muscle, it achieves local tissue concentrations comparable to or exceeding oral NSAIDs in the target tissue, while producing only a fraction of the systemic blood levels. This makes it an attractive option for osteoarthritis of the knee and hand in patients for whom systemic NSAIDs carry meaningful GI or cardiovascular risk. Voltaren 1% gel is now available over the counter.

Lidocaine patches (Lidoderm, now available generically) are FDA-approved for postherpetic neuralgia — the burning neuropathic pain that persists after a shingles outbreak — and are also used off-label for other localized neuropathic and musculoskeletal pain. Lidocaine is a sodium channel blocker: applied topically, it stabilizes nerve membranes and reduces abnormal pain signaling in peripheral nerves at the application site. Systemic absorption is minimal when patches are used as directed, making them exceptionally safe for patients who cannot tolerate other analgesics.

Capsaicin is derived from chili peppers and works through a mechanism that is initially counterintuitive: it activates TRPV1 receptors in sensory nerve fibers, causing an initial burning sensation, then depletes substance P — a key neuropeptide involved in pain signaling — from those nerve fibers. With repeated application, the nerve fibers become desensitized. A high-concentration capsaicin patch (Qutenza, 8%) is FDA-approved for postherpetic neuralgia and HIV-associated neuropathy. Low-concentration OTC capsaicin creams are widely used for musculoskeletal pain.

Muscle Relaxants

When pain arises from or is significantly aggravated by muscle spasm — low back strain, cervical strain (whiplash), fibromyalgia — muscle relaxant medications can provide meaningful adjunctive relief. They are most effective for short-term use in acute musculoskeletal pain.

Cyclobenzaprine (Flexeril) is structurally related to tricyclic antidepressants and acts centrally in the brainstem to reduce muscle hyperactivity. It is one of the most commonly prescribed muscle relaxants for acute back and neck pain. Sedation is its most prominent side effect — which can be either a drawback (for daytime use) or a benefit (when nighttime muscle spasm is disrupting sleep). It is not recommended for older adults due to its anticholinergic properties.

Methocarbamol (Robaxin) is another centrally acting muscle relaxant with a somewhat different side effect profile, generally considered somewhat less sedating than cyclobenzaprine and with fewer anticholinergic effects, making it a somewhat better option for patients in whom sedation is a concern.

Baclofen and tizanidine are additional muscle relaxants used for spasticity associated with neurological conditions (multiple sclerosis, spinal cord injury) and chronic musculoskeletal pain, respectively.

Medications for Neuropathic Pain

Neuropathic pain — burning, shooting, electric-shock pain from nerve damage or dysfunction — demands a different pharmacological approach than nociceptive pain. The following agents are the cornerstones of neuropathic pain management and are recommended as first-line treatments by major pain medicine and neurology organizations.

Gabapentin (Neurontin) and pregabalin (Lyrica) are anticonvulsants that bind to the alpha-2-delta subunit of voltage-gated calcium channels in the dorsal horn of the spinal cord and in peripheral sensory neurons. This binding reduces calcium influx, dampening the release of excitatory neurotransmitters that drive pain signaling. The result is a reduction in the hypersensitized, amplified pain transmission that characterizes neuropathic conditions. Both drugs are FDA-approved for diabetic peripheral neuropathy and postherpetic neuralgia; pregabalin is also approved for fibromyalgia and spinal cord injury pain. Gabapentin is used extensively off-label for many neuropathic conditions. Common side effects include dizziness, sedation, and cognitive slowing; weight gain is also notable with long-term use. Both have been increasingly recognized as having abuse potential, particularly in patients with prior substance use disorders. Available strengths vary widely to allow gradual titration.

Duloxetine (Cymbalta) is a serotonin-norepinephrine reuptake inhibitor (SNRI) that is FDA-approved not only as an antidepressant but specifically for diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain (including chronic low back pain and osteoarthritis). By increasing synaptic concentrations of serotonin and norepinephrine in the descending pain-modulation pathways of the spinal cord, duloxetine enhances the brain's natural pain-suppressing circuitry. This makes it effective across both neuropathic and central sensitization pain types — and useful even in patients who are not depressed.

Tricyclic antidepressants (TCAs) — particularly amitriptyline and nortriptyline — are among the oldest and most extensively studied treatments for neuropathic pain. They work through multiple mechanisms including norepinephrine and serotonin reuptake inhibition, sodium channel blockade, and NMDA receptor modulation. Amitriptyline is often prescribed at low amounts for neuropathic pain — amounts well below those used for depression — and has evidence supporting its use in postherpetic neuralgia, diabetic neuropathy, and migraine prevention. The main limitations are significant anticholinergic side effects (dry mouth, constipation, urinary retention, blurred vision), cardiac arrhythmia risk at higher levels, and sedation. TCAs are generally used with caution in older adults and avoided in patients with cardiac conduction abnormalities.

Venlafaxine, another SNRI, has evidence for neuropathic pain and is sometimes used when duloxetine is not tolerated. SNRIs as a class represent an underutilized option for chronic pain that combines analgesic benefit with mood stabilization — relevant given the bidirectional relationship between chronic pain and depression.

Interventional and Non-Pharmacologic Options

Nerve blocks and epidural steroid injections deliver corticosteroids (and sometimes local anesthetics) directly to sites of nerve compression or inflammation. Epidural steroid injections for lumbar radiculopathy (sciatica) can provide significant pain relief and functional improvement for weeks to months, often allowing patients to engage in physical therapy more effectively. Facet joint injections, trigger point injections, and diagnostic nerve blocks serve similar targeted roles. These interventions are not cures but can be important components of a multimodal strategy.

Physical therapy is consistently undervalued as a pain treatment. Exercise and movement improve circulation, reduce inflammation, strengthen supporting muscles, improve posture and biomechanics, and promote endogenous pain modulation through endorphin release and central sensitization reversal. For chronic low back pain, neck pain, and most musculoskeletal conditions, physical therapy is at least as effective as medication in the intermediate and long term — often more so when it comes to functional outcomes. The challenge is adherence and accessibility.

Transcutaneous electrical nerve stimulation (TENS) uses low-level electrical current delivered through skin electrodes to modulate pain signals. Evidence is moderate and patient responses are variable, but TENS carries negligible risk, can be self-administered, and provides meaningful relief for some patients with chronic musculoskeletal or neuropathic pain.

Acupuncture has accumulated a meaningful evidence base for certain pain conditions, including chronic low back pain, neck pain, osteoarthritis, and headache. Multiple systematic reviews and meta-analyses have found it superior to sham acupuncture and to usual care for these conditions. The mechanisms remain debated — neuroimaging studies suggest effects on pain-processing brain regions — but the clinical evidence supports its use as an adjunct in chronic pain management.

Cognitive behavioral therapy (CBT) for chronic pain addresses the psychological dimensions of pain experience — pain catastrophizing, fear-avoidance behavior, sleep disruption, and mood — that substantially amplify and perpetuate chronic pain. Evidence for CBT's effectiveness in reducing pain intensity and, especially, pain-related disability is robust across multiple chronic pain conditions. In conditions with strong central sensitization components (fibromyalgia, chronic pelvic pain, complex regional pain syndrome), CBT may be one of the most effective tools available.

Opioids: When They Are Appropriate

The pendulum of opioid prescribing has swung so far that there is now a real risk of under-treating pain in patients who genuinely need opioids. The goal is not to eliminate opioid use — it is to use opioids where they are clearly appropriate, at the lowest effective levels, for the appropriate duration, with monitoring and informed consent. Understanding when opioids are the right tool is as important as understanding when they are not.

Appropriate Indications

Opioids have clear, well-established roles in several clinical contexts:

• Cancer pain: Active cancer pain, particularly from solid tumors causing bone invasion, visceral pain, or nerve compression, often requires opioid analgesia. The WHO ladder was originally designed for cancer pain precisely because it is often severe, progressive, and refractory to non-opioid approaches alone. Patients with cancer deserve aggressive, effective pain management.
• Post-surgical pain: Moderate to severe pain in the immediate post-operative period is a legitimate indication for short-course opioid use, typically combined with non-opioid multimodal analgesia. Modern "opioid-sparing" surgical protocols use multimodal approaches specifically to reduce opioid requirements while maintaining adequate pain control.
• Acute severe injury: Traumatic injury — major fractures, burns, significant soft tissue injury — often produces pain of a severity that warrants opioid analgesics for a limited acute period.
• End-of-life and palliative care: Patients with serious, life-limiting illness and pain or dyspnea often benefit substantially from opioids as part of comprehensive palliative care. Concerns about dependence and tolerance are appropriately secondary to quality of life and comfort in this context.
• Sickle cell disease vasoocclusive crisis: The severe, acute pain of sickle cell crisis is one of the most undertreated pain conditions in medicine; opioids are a core component of crisis management.

How Opioids Work

Opioids exert their analgesic effects primarily through agonism at mu-opioid receptors (MOR), though they also interact with kappa and delta opioid receptors to varying degrees. Mu-opioid receptors are distributed throughout the central and peripheral nervous system — in the brain (periaqueductal gray, thalamus, cortex), in the spinal cord dorsal horn, and in peripheral sensory neurons. When an opioid binds to these receptors, it activates G-protein-coupled signaling pathways that reduce neuronal excitability: potassium channels open (hyperpolarizing the cell), calcium channels close (reducing neurotransmitter release), and adenylyl cyclase is inhibited. The net result is suppression of pain signal transmission at multiple levels simultaneously — a powerful mechanism that explains why opioids are effective for even severe pain.

The same receptors are present in the brainstem's respiratory control centers (explaining the risk of respiratory depression in overdose), in the gut (explaining constipation — essentially universal with opioid use), in the reward circuitry of the brain (explaining euphoria and addiction risk), and in the immune system and hormonal axes (explaining some longer-term effects of chronic opioid therapy).

Short-Acting and Long-Acting Formulations

Short-acting opioids (immediate-release formulations) produce relatively rapid onset and shorter duration of effect, typically three to six hours depending on the specific agent. They are appropriate for acute pain, breakthrough pain in cancer patients, and situations where pain is intermittent or the clinical situation is evolving. Commonly used short-acting opioids include:

• Oxycodone (Roxicodone; also in combination with acetaminophen as Percocet) — a semi-synthetic opioid with strong mu-receptor affinity; available in multiple strengths
• Hydrocodone (in combination with acetaminophen as Vicodin, Norco; available as pure hydrocodone ER as Zohydro) — the most-prescribed opioid in the U.S. for many years; similar in effect to oxycodone
• Morphine (MSIR, others) — the prototypical opioid; the reference compound against which other opioids are compared using oral morphine equivalents (OME or MME)
• Codeine — a prodrug converted to morphine by the CYP2D6 enzyme; relatively weak analgesic; substantial variability in effect based on metabolizer status; poor CYP2D6 metabolizers get little analgesia, ultra-rapid metabolizers may experience dangerously elevated morphine levels
• Tramadol — a "weak" or atypical opioid (see FAQ section below); Schedule IV; also inhibits serotonin and norepinephrine reuptake

Long-acting (extended-release) opioid formulations were developed to provide more stable blood levels over time, reducing the peaks associated with euphoria and troughs associated with breakthrough pain — in theory, a more consistent analgesic effect with potentially lower addiction risk. They include extended-release oxycodone (OxyContin), extended-release morphine (MS Contin, Kadian), transdermal fentanyl (Duragesic patches), and buprenorphine transdermal patch (Butrans — a partial agonist with a ceiling effect on respiratory depression). Long-acting opioids are generally reserved for patients with continuous, around-the-clock pain who have already been stabilized on opioid therapy, such as cancer patients. Their use in chronic non-cancer pain has been substantially curtailed following recognition that long-term opioid therapy for non-cancer chronic pain rarely produces durable functional improvement.

Risks and Complications of Opioid Therapy

Physical dependence develops with regular opioid use within days to weeks: the body adapts to the presence of the drug, and removal causes a withdrawal syndrome — anxiety, agitation, sweating, muscle aches, nausea, diarrhea, and intense drug craving. Physical dependence is physiological and expected; it is not the same as addiction. Addiction (opioid use disorder) is a complex behavioral condition involving compulsive use despite harm, loss of control, and continued use despite negative consequences. Physical dependence can occur in patients who do not have addiction; conversely, addiction involves more than just physical dependence.

Tolerance develops when the same amount of opioid produces diminishing analgesic effect over time, requiring escalating amounts for equivalent pain relief. Tolerance is a consequence of receptor-level adaptations to persistent opioid stimulation. It drives dose escalation in long-term opioid therapy and is one reason that opioids often provide less durable benefit for chronic non-cancer pain than initially expected.

Opioid-induced hyperalgesia (OIH) is a paradoxical and clinically important phenomenon: with long-term opioid exposure, the nervous system undergoes neuroplastic changes that actually increase pain sensitivity — the opposite of the intended effect. Patients with OIH experience diffuse, widespread pain that worsens rather than improves with continued opioid therapy. OIH can be distinguished from tolerance by its diffuse nature and the fact that dose increases worsen rather than improve the pain. OIH is one of the most compelling arguments against indefinite high-dose opioid therapy for chronic non-cancer pain.

Overdose and respiratory depression remain the most dangerous risks. Opioids depress the brainstem respiratory centers in a dose-dependent fashion. When opioid blood levels rise above a critical threshold — whether from too large a dose, interactions with other CNS depressants (benzodiazepines, alcohol, muscle relaxants), or in tolerant patients who suddenly have their tolerance removed (after a period of abstinence), or in someone who takes more than prescribed — respiratory drive can be suppressed to the point of hypoxic brain injury or death. The opioid reversal agent naloxone (Narcan) blocks mu-opioid receptors and can rapidly reverse respiratory depression; its widespread availability through programs offering it without a prescription has saved many lives.

Other opioid side effects include: constipation (essentially universal — unlike most opioid effects, the gut does not develop tolerance to this, and opioid-induced constipation often requires ongoing management with peripherally acting mu-opioid receptor antagonists like methylnaltrexone or naloxegol); nausea; sedation; cognitive impairment; hormonal disruption (reduced testosterone and libido with long-term use); and immune modulation.

The Opioid Crisis: Context and Scale

The United States opioid crisis is among the most consequential public health failures in modern history. It developed in three overlapping waves. The first, from the late 1990s, involved prescription opioids — particularly OxyContin — which were aggressively and misleadingly marketed by Purdue Pharma and others as safer and less addictive than older opioids. Prescribing rates climbed dramatically; opioid use disorder followed. The second wave began around 2010 as heroin became cheaper and more available, filling demand among people who had become dependent on prescription opioids. The third and ongoing wave, beginning around 2013, has been driven by illicit fentanyl — a synthetic opioid roughly 100 times more potent than morphine — manufactured clandestinely and increasingly mixed into heroin and counterfeit pills.

The CDC estimates that more than 80,000 Americans died from opioid overdose in 2021 — with numbers remaining in the same range through subsequent years — representing the majority of all drug overdose deaths. The cumulative toll since 2000 exceeds 500,000 deaths. Communities across the country — rural Appalachia, suburban cities, Indigenous communities — have been devastated. The social costs, including healthcare expenditures, lost productivity, child welfare system strain, and incarceration, are in the hundreds of billions annually.

The crisis generated important policy responses: the 2016 and 2022 CDC prescribing guidelines; DEA restrictions on opioid manufacturing quotas; state prescription drug monitoring programs (PDMPs) that allow prescribers and pharmacists to review a patient's controlled substance history; enhanced naloxone access; expansion of treatment for opioid use disorder; and legal accountability for pharmaceutical companies and distributors whose conduct contributed to the crisis. Purdue Pharma agreed to a multi-billion-dollar settlement, and Sackler family members faced personal liability.

Treatment of Opioid Use Disorder

Opioid use disorder (OUD) is a chronic brain condition, not a moral failing, and it responds to treatment. Three FDA-approved medications significantly reduce opioid cravings, withdrawal, and illicit opioid use — and each has evidence showing they reduce mortality from overdose.

Buprenorphine is a partial mu-opioid receptor agonist — it binds to the mu receptor and activates it, but with a "ceiling effect" that limits respiratory depression above a certain level, making it substantially safer in overdose than full agonists. Buprenorphine has high receptor affinity, meaning it binds tightly and can displace other opioids, which makes it useful both for reducing cravings and for blocking the effects of other opioids. It is most commonly prescribed as the combination product Suboxone (buprenorphine/naloxone films or tablets), in which naloxone is added to deter misuse: when taken as directed sublingually, the naloxone is poorly absorbed systemically and has minimal effect; if the product is crushed and injected, the naloxone precipitates immediate withdrawal. Buprenorphine can be prescribed in office-based settings by qualified providers — a significant advantage over methadone.

Methadone, when used for OUD, is a full mu-opioid agonist dispensed through federally certified opioid treatment programs (OTPs), typically requiring daily in-person visits for observed dosing in early treatment. Methadone has an exceptionally long half-life, providing stable blood levels without peaks and troughs. It is one of the most extensively studied and effective treatments for OUD, with decades of evidence. Its main limitations are the need for OTP dispensing (creating access barriers for many patients) and cardiac arrhythmia risk (QTc prolongation) at higher levels, which requires EKG monitoring.

Naltrexone (Vivitrol, extended-release injectable; or daily oral tablets) is an opioid antagonist — it blocks mu-opioid receptors entirely, preventing any opioid from producing effect. It is not an opioid and produces no physical dependence. It is effective in motivated patients who are fully detoxified from opioids (starting before detox is complete precipitates severe withdrawal). The monthly injectable formulation eliminates the adherence problem with daily oral dosing. Naltrexone works best for patients in structured support environments (drug courts, healthcare workers, highly motivated individuals) and is also FDA-approved for alcohol use disorder.

All three medications are considered medication-assisted treatment (MAT) or, preferably, medications for opioid use disorder (MOUD). They are substantially more effective at reducing opioid use, preventing relapse, and preventing overdose death than abstinence-only approaches. Withholding these medications from people with OUD — including those who are incarcerated, hospitalized, or in drug court programs — is widely recognized as a form of medical neglect.

Special Populations: Tailoring Pain Management

Elderly Patients

Older adults are at higher risk for adverse effects from nearly every class of analgesic. NSAIDs carry substantially elevated GI bleeding risk in older adults (the gastric mucosa is more vulnerable, and frail patients bleed more significantly when ulcers do form), as well as greater cardiovascular and renal risk. The American Geriatrics Society's Beers Criteria — a guide to potentially inappropriate medications in older adults — advises caution or avoidance of most NSAIDs and cyclobenzaprine in elderly patients. Acetaminophen, at conservative levels, is generally the preferred first-line oral analgesic for older adults with chronic pain and preserved liver function. Topical agents deserve special emphasis in this population: topical diclofenac and lidocaine patches provide localized relief with minimal systemic exposure. When opioids are needed in older adults, lower starting levels and longer dose intervals are appropriate given reduced renal clearance and increased CNS sensitivity.

Kidney Disease

Chronic kidney disease significantly constrains analgesic options. NSAIDs — including even short-term use — can precipitously worsen kidney function in patients with CKD by inhibiting prostaglandin-mediated afferent arteriolar dilation; the kidney relies on this mechanism to maintain glomerular filtration rate when systemic perfusion is compromised. NSAIDs are generally contraindicated in moderate to severe CKD. Acetaminophen, at appropriate levels, is generally safer in CKD than NSAIDs and is considered the preferred systemic analgesic for mild to moderate pain in this population. Opioid use in CKD requires careful selection and monitoring: some opioid metabolites are renally cleared and accumulate dangerously in kidney failure. Buprenorphine, unusually among opioids, is cleared primarily hepatically rather than renally and is considered relatively safer in CKD than other opioids when opioid therapy is required.

Liver Disease

Significant liver disease changes the safety calculus for acetaminophen: reduced hepatic glutathione and impaired metabolic capacity lower the threshold for NAPQI accumulation and hepatotoxicity. Acetaminophen is not necessarily contraindicated in mild liver disease, but the recommended daily limit is substantially lower than in healthy individuals, and alcohol use must be zero. NSAIDs carry their own hepatic risks at high levels, as well as the risk of precipitating hepatic decompensation (ascites, hepatorenal syndrome) in patients with cirrhosis and portal hypertension. Opioids, particularly morphine and codeine, may have prolonged or exaggerated effects in severe liver disease due to impaired first-pass metabolism. Management of pain in patients with significant liver disease requires expert guidance.

Multimodal Analgesia: The Most Effective Approach

Multimodal analgesia — combining medications and non-pharmacologic treatments that work through different mechanisms — is now the dominant paradigm in pain medicine, and for good reason. Pain is processed at multiple sites simultaneously (peripheral nerves, spinal cord, brain), through multiple molecular mechanisms. No single drug class addresses all of these pathways. By targeting multiple mechanisms simultaneously, multimodal approaches achieve better pain control at lower amounts of each individual agent, reducing the dose-dependent side effects of any single drug.

In post-surgical pain management, the multimodal approach is well-established: a scheduled NSAID or acetaminophen to reduce baseline inflammatory pain, a regional nerve block for surgical site analgesia, and opioids reserved for breakthrough pain only — rather than scheduled opioids as the primary analgesic. This "opioid-sparing" strategy consistently reduces total opioid consumption and speeds recovery. For chronic pain, combining a peripheral agent (topical NSAID or lidocaine), a central agent (duloxetine or gabapentin), and a non-pharmacologic approach (physical therapy and CBT) frequently produces better outcomes than maximizing any single agent. Multimodal thinking reframes pain management as an engineering problem: identify the pain types present, select tools that address each mechanism, combine them intelligently, and individualize to the patient.

Comparison: Opioid vs. Non-Opioid Approaches

Frequently Asked Questions